NDATOPICALSOLUTIONPriority Review
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
Priority Review
ROGAINE (FOR MEN) (minoxidil) by Design Pharmaceuticals is clinical pharmacology 1. First approved in 1988.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROGAINE (FOR MEN) is a topical minoxidil solution used to treat androgenetic alopecia and male pattern hair loss. It works as an arteriolar vasodilator that enhances microcirculatory blood flow to hair follicles, promoting hair growth and slowing hair loss. The exact mechanism of action in hair regrowth is not fully elucidated but involves increased blood flow to the scalp.
LOE Approaching
Product approaching loss of exclusivity with mature market presence; commercial teams should anticipate generic erosion and strategy shifts toward line extensions or combination therapies.
Mechanism of Action
CLINICAL PHARMACOLOGY 1. General Pharmacologic Properties Minoxidil is an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. Microcirculatory blood flow in animals is enhanced or maintained…
Worked on ROGAINE (FOR MEN) at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.